Parvo Antibody

What Sets AESC Apart

At Animal Emergency & Specialty Clinic of Northwest Arkansas (AESC), we are excited to offer an innovative new treatment option for dogs suffering from canine parvovirus: the Canine Parvovirus Monoclonal Antibody (CPMA). Parvo is a highly contagious virus and one of the most common causes of viral illness in dogs, often leading to severe health issues. Traditionally, supportive care was the primary treatment available, but with CPMA, we now have a targeted antiviral option that can make a significant difference in the treatment outcomes.

Why Choose CPMA for Parvo Treatment?

• Single Dose Efficiency: CPMA is administered in just one intravenous dose, streamlining the treatment process. This approach is designed to reduce the virus’s impact, potentially shortening the duration of the illness and improving recovery rates.
• Clinically Proven Results: Studies have shown that dogs treated with CPMA recover faster from severe symptoms like vomiting, lethargy, and appetite loss. This means less distress for your pet and a quicker return to normal health.
• Safe for Puppies: CPMA has been tested and found safe for use in puppies as young as six weeks. The treatment is well tolerated, with most dogs experiencing mild or no side effects, which typically resolve within a day.
• Faster Homecoming: By potentially decreasing the duration of hospital stays, CPMA not only helps improve your dog’s health but also allows them to return home sooner, where they can continue recovering in a loving environment. As a leading provider of specialized veterinary care, AESC is proud to include CPMA among our treatment options, giving hope to dogs affected by parvo and their families. Our commitment to embracing the latest advancements ensures your pets receive the highest standard of care in their time of need.